Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Reaffirmed by HC Wainwright

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 86.92% from the stock’s previous close.

TRVI has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Friday, October 4th. Leerink Partners started coverage on Trevi Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. B. Riley reaffirmed a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.43.

Trevi Therapeutics Stock Performance

TRVI opened at $3.21 on Tuesday. Trevi Therapeutics has a one year low of $0.97 and a one year high of $4.00. The company has a market cap of $226.10 million, a price-to-earnings ratio of -9.44 and a beta of 0.97. The business’s fifty day moving average is $3.12 and its two-hundred day moving average is $2.89.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter in the previous year, the business earned ($0.07) EPS. On average, analysts predict that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Thomas Sciascia sold 18,660 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the transaction, the insider now owns 220,315 shares of the company’s stock, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $644,205.26. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,355 shares of company stock valued at $116,663. Insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TRVI. Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics during the first quarter worth about $47,000. Hsbc Holdings PLC acquired a new stake in Trevi Therapeutics during the 2nd quarter valued at approximately $61,000. SG Americas Securities LLC purchased a new stake in Trevi Therapeutics during the 3rd quarter worth approximately $78,000. The Manufacturers Life Insurance Company raised its position in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after purchasing an additional 11,450 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after buying an additional 7,902 shares during the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.